← Erasca, Inc. (ERAS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Erasca, Inc. (ERAS)
Pharmaceutical Preparations · market cap $5.1B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Erasca, Inc. (ERAS) is a small-cap oncology-focused pharmaceutical company with 103 employees and a ~$5.76B market cap, built around inhibiting the RAS/MAPK pathway in cancer. Its lead asset, naporafenib, is in Phase 3 development for advanced or metastatic NRAS-mutant melanoma, with a pipeline that also includes encorafenib in metastatic colorectal cancer and ERAS-007 in solid tumors. The company carries only $47.3M in cash, implying a runway of approximately five months, making near-term financing essentially a certainty.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Naporafenib | Phase 3 | Advanced or Metastatic NRAS-mutant Melanoma |
| Encorafenib | Phase 2 | Metastatic Colorectal Cancer |
| ERAS-007 | Phase 2 | Advanced or Metastatic Solid Tumors |
Price & technical context
3-month
-21.1%
6-month
-12.2%
12-month
+568.8%
52-wk range
$2.13–$22.47
vs 50-day MA
-14.2%
vs 200-day MA
+4.7%
Realized vol
107.6%
Max drawdown
-67.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ERAS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.